US5004723038

We assign a fundamental rating of **3** out of 10 to **PHG**. **PHG** was compared to 199 industry peers in the **Health Care Equipment & Supplies** industry. Both the profitability and financial health of **PHG** have multiple concerns. **PHG** is valued quite cheap, while showing a decent growth score. This is a good combination!

In the past year **PHG** had a positive cash flow from operations.

In multiple years **PHG** reported negative net income over the last 5 years.

The reported operating cash flow has been mixed in the past 5 years: **PHG** reported negative operating cash flow in multiple years.

With a decent **Return On Assets** value of **-6.87%**, **PHG** is doing good in the industry, outperforming **60.10%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -6.87% | ||

ROE | -16.72% | ||

ROIC | N/A |

ROA(3y)3.25%

ROA(5y)3.65%

ROE(3y)6.95%

ROE(5y)7.83%

ROIC(3y)N/A

ROIC(5y)N/A

Looking at the **Gross Margin**, with a value of **41.75%**, **PHG** is doing worse than **64.14%** of the companies in the same industry.

In the last couple of years the **Gross Margin** of **PHG** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 41.75% |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.14%

GM growth 5Y-2.48%

There is no outstanding debt for **PHG**. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

The **Altman-Z score** of **PHG** (**1.49**) is comparable to the rest of the industry.

The Debt to FCF ratio of **PHG** is **684.67**, which is on the high side as it means it would take **PHG**, **684.67** years of fcf income to pay off all of its debts.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.59 | ||

Debt/FCF | 684.67 | ||

Altman-Z | 1.49 |

ROIC/WACCN/A

WACC6.26%

A Quick Ratio of **0.69** indicates that **PHG** may have some problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.2 | ||

Quick Ratio | 0.69 |

The earnings per share for **PHG** have decreased by **-7.94%** in the last year.

The earnings per share for **PHG** have been decreasing by **-11.60%** on average. This is quite bad

The **Revenue** has been growing slightly by **0.05%** on average over the past years.

EPS 1Y (TTM)-7.94%

EPS 3Y-22.11%

EPS 5Y-11.6%

EPS growth Q2Q100%

Revenue 1Y (TTM)6.83%

Revenue growth 3Y1.3%

Revenue growth 5Y0.05%

Revenue growth Q2Q7.01%

The **Earnings Per Share** is expected to grow by **19.83%** on average over the next years. This is quite good.

Based on estimates for the next years, **PHG** will show a small growth in **Revenue**. The Revenue will grow by **5.49%** on average per year.

EPS Next Y37.55%

EPS Next 2Y23.44%

EPS Next 3Y22.33%

EPS Next 5Y19.83%

Revenue Next Year6.54%

Revenue Next 2Y5.16%

Revenue Next 3Y5.02%

Revenue Next 5Y5.49%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

With a **Price/Earnings** ratio of **16.09**, **PHG** is valued correctly.

Based on the **Price/Earnings** ratio, **PHG** is valued cheaply inside the industry as 90.40% of the companies are valued more expensively.

The **Price/Forward Earnings** ratio is **12.90**, which indicates a correct valuation of **PHG**.

Compared to the rest of the industry, the **Price/Forward Earnings** ratio of **PHG** indicates a rather cheap valuation: **PHG** is cheaper than 95.96% of the companies listed in the same industry.

When comparing the **Price/Forward Earnings** ratio of **PHG** to the average of the S&P500 Index (**21.51**), we can say **PHG** is valued slightly cheaper.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 16.09 | ||

Fwd PE | 12.9 |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **PHG** indicates a rather cheap valuation: **PHG** is cheaper than 81.31% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 1407.69 | ||

EV/EBITDA | 20.98 |

A more expensive valuation may be justified as **PHG**'s earnings are expected to grow with **22.33%** in the coming years.

PEG (NY)0.43

PEG (5Y)N/A

EPS Next 2Y23.44%

EPS Next 3Y22.33%

No dividends for **PHG**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**KONINKLIJKE PHILIPS NVR- NY**

NYSE:PHG (2/20/2024, 9:35:08 AM)

**20.115**

**-0.2 (-0.96%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap18.20B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 16.09 | ||

Fwd PE | 12.9 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)0.43

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -6.87% | ||

ROE | -16.72% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 41.75% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.62

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.59 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.2 | ||

Quick Ratio | 0.69 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-7.94%

EPS 3Y-22.11%

EPS 5Y

EPS growth Q2Q

EPS Next Y37.55%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)6.83%

Revenue growth 3Y1.3%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y